US FDA extends comment period for post-marketing safety reporting rule
This article was originally published in RAJ Devices
Executive Summary
The US Food and Drug Administration is providing more time for stakeholders to respond to its proposal to establish post-marketing safety reporting requirements specific to combination products1,2.